Turning Point Therapeutics, Inc.
(NASDAQ : TPTX)

( )
TPTX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. -0.82%33.750.9%$1145.03m
JNJJohnson & Johnson 0.29%143.270.7%$1079.06m
BMYBristol-Myers Squibb Co. -1.19%59.571.0%$967.54m
MRKMerck & Co., Inc. -1.07%77.880.7%$816.26m
ABBVAbbVie, Inc. -0.03%99.321.9%$785.33m
LLYEli Lilly & Co. 1.42%169.121.1%$695.99m
AZNAstraZeneca Plc 1.35%54.191.2%$290.07m
VXRTVaxart, Inc. -8.12%8.150.0%$286.48m
RPRXRoyalty Pharma Plc 2.06%48.020.1%$226.50m
NVSNovartis AG 0.36%88.120.2%$151.51m
RGENRepligen Corp. 0.92%125.287.1%$117.23m
GSKGlaxoSmithKline Plc 0.84%40.720.2%$112.42m
NVONovo Nordisk A/S 1.25%65.870.1%$94.18m
RETAReata Pharmaceuticals, Inc. 1.52%158.003.4%$82.12m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 8.02%77.860.0%$73.21m

Company Profile

Turning Point Therapeutics, Inc. engages in the discovery and development of precision medicines for cancer and other diseases. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by J. Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA.